Patents Assigned to Genentech
  • Publication number: 20250002575
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for detection of IL-33 in biological samples.
    Type: Application
    Filed: May 8, 2024
    Publication date: January 2, 2025
    Applicant: Genentech, Inc.
    Inventors: John Hok Nin LOWE, Kelly Michele LOYET, Elaine MAI, Mauricio Silva MAIA, Gerald R. NAKAMURA, Jack BEVERS, III, Hiu Nam CHAN, Laetitia D. COMPS-AGRAR, Racquel CORPUZ
  • Publication number: 20250000473
    Abstract: The present disclosure relates to techniques for segmenting tumors with positron emission tomography (PET) using deep convolutional neural networks for image and lesion metabolism analysis.
    Type: Application
    Filed: September 12, 2024
    Publication date: January 2, 2025
    Applicant: GENENTECH, INC.
    Inventors: Nils Gustav Thomas BENGTSSON, Richard Alan Duray CARANO, Alexander James Stephen CHAMPION DE CRESPIGNY, Jill Osborn FREDRICKSON, Mohamed Skander JEMAA
  • Patent number: 12183434
    Abstract: Provided herein are diagnostic and therapeutic methods for the treatment of cancer using polygenic risk scores (PRSs) for dermatological autoimmune diseases. In particular, the invention provides methods for patient selection and methods of treatment.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: December 31, 2024
    Assignee: Genentech, Inc.
    Inventors: Zia Khan, Matthew Lawrence Albert, G Scott Chandler
  • Publication number: 20240426835
    Abstract: This application relates to random polymer libraries and specific polymers that can be used, for example, in stabilizing high concentration protein compositions, such as high concentration antibody compositions.
    Type: Application
    Filed: September 5, 2024
    Publication date: December 26, 2024
    Applicant: Genentech, Inc.
    Inventors: Ann Marie Woys, Kathryn Margaret Mansfield Messina
  • Publication number: 20240425610
    Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Application
    Filed: September 4, 2024
    Publication date: December 26, 2024
    Applicant: Genentech, Inc.
    Inventors: Yung-Hsiang KAO, Michael W. LAIRD, Melody Trexler SCHMIDT, Rita L. WONG, Daniel P. HEWITT
  • Publication number: 20240425615
    Abstract: The present application discloses high-concentration monoclonal antibody formulations suitable for subcutaneous administration, e.g. via a pre-filled syringe. In particular, it discloses a formulation comprising a spray dried monoclonal antibody at a concentration of about 200 mg/mL or more suspended in a non-aqueous suspension vehicle where the viscocity of the suspension vehicle is less than about 20 centipoise. Also disclosed are: a subcutaneous administration device with the formulation therein, a method of making the formulation, a method of making an article of manufacture comprising the suspension formulation, use of the formulation in the preparation of a medicament, and a method of treating a patient with the formulation.
    Type: Application
    Filed: May 23, 2024
    Publication date: December 26, 2024
    Applicant: Genentech, Inc.
    Inventors: Nicholas J. ARMSTRONG, Mayumi N. BOWEN, Yuh-Fun MAA
  • Patent number: 12171805
    Abstract: The invention relates to compositions (e.g., pharmaceutical compositions) that include, for example, IL-22 Fc fusion proteins, methods of making the same, and methods of using the same, e.g., for the treatment of diseases (e.g., IBD).
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: December 24, 2024
    Assignee: Genentech, Inc.
    Inventors: Bruce Kabakoff, Cecilia Wong Man Sai
  • Patent number: 12171716
    Abstract: The needless vial assemblies described herein allow for the access to the contents of a vial, such as a medication, using a syringe without a needle. In some designs, the vial includes a vial neck, which is itself a syringe interface. The vial assemblies also include a cap with a plug, which can be used to seal the vial assembly. The present disclosure further provides methods of filling a vial assembly and methods of filling a syringe using the vial assemblies described herein.
    Type: Grant
    Filed: November 15, 2023
    Date of Patent: December 24, 2024
    Assignee: Genentech, Inc.
    Inventors: Geoffrey Wise, Ajay Deshmukh, Lionel Vedrine
  • Patent number: 12172982
    Abstract: Provided herein are methods of synthesizing quinazoline compounds comprising at least one atropisomeric center.
    Type: Grant
    Filed: August 10, 2021
    Date of Patent: December 24, 2024
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Ngiap-Kie Lim, Jeff Shen, Lauren Elizabeth Sirois, Jacob C. Timmerman, Etienne Trachsel, Nicholas Andrew White, Jie Xu, Haiming Zhang, Stephan Bachmann, Raphael Bigler, Kyle Bradley Pascual Clagg, Antonio Giovanni Dipasquale, Francis Gosselin, Ugo Jonathan Orcel, Roland Christoph Meier
  • Patent number: 12171763
    Abstract: Provided herein are combination therapies (compositions) and methods and uses thereof for the treatment lung cancer, where the combination therapies comprise Compound 1 or a pharmaceutically acceptable salt thereof as described herein and a PD-L1 binding antagonist (e.g., atezolizumab).
    Type: Grant
    Filed: November 11, 2021
    Date of Patent: December 24, 2024
    Assignee: Genentech, Inc.
    Inventors: Marie Evangelista, Mark Andrew Merchant, Jennifer Lee Schutzman, Ting-Kun Mark Lin, Stephanie Royer Joo, Sandhya Vinayak Mandlekar
  • Patent number: 12171688
    Abstract: An apparatus includes a body, and anchoring feature, and a guide feature. The body is sized and configured to be positioned on an eye of a patient. The anchoring feature is configured to secure the body to the eye of the patient. The guide feature is configured to guide a cannula into a scleral incision formed in the eye of the patient along a path that is substantially tangential relative to the eye of the patient. The guide feature is sized and configured to allow the cannula to pivot laterally through a range of angular motion at the scleral incision.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: December 24, 2024
    Assignee: Genentech, Inc.
    Inventors: Thomas E. Meyer, Mark Hedgeland, Benjamin Ko, Thomas Gernetzke, Olivia Enneking, Eric Kennedy, Robert Roth, Michael Auld, Jacob Schubert, Samuel Ridgley
  • Patent number: 12173080
    Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Grant
    Filed: September 4, 2024
    Date of Patent: December 24, 2024
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • Publication number: 20240418709
    Abstract: Provided herein are methods for generating a solid antigen/carrier protein gel for immunohistochemistry (IHC), as well as gels, kits and methods of use thereto. In particular, the methods, gels and kits provided herein include a purified antigen such as a polypeptide antigen, and a carrier protein such as an albumin protein, an egg white protein or mixture of egg white proteins, gelatin, or poly-lysine. Examples are provided in which the purified antigen is cross-linked to the carrier protein in the solid antigen/carrier protein gel.
    Type: Application
    Filed: May 20, 2024
    Publication date: December 19, 2024
    Applicant: Genentech, Inc.
    Inventors: Kathy HĂ–TZEL, Franklin V. PEALE, Jr., Charles HAVNAR, Linda RANGELL, Debra Y. DUNLAP
  • Publication number: 20240418731
    Abstract: The present disclosure provides methods of identifying a disease-specific immunogenic peptide through a series of selection steps. Immunogenic epitopes identified by methods of the present disclosure are applicable for use in peptide-based immunotherapy, preferably cancer therapy. Furthermore, the methods of the present disclosure may be performed in a high-throughput manner and serve as a means of personalized vaccine development and therapy. Also provided are compositions of immunogenic peptides as well as methods of treatment comprising said compositions.
    Type: Application
    Filed: July 2, 2024
    Publication date: December 19, 2024
    Applicant: Genentech, Inc.
    Inventors: Lelia DELAMARRE, Patrick LUPARDUS, Ira MELLMAN, Mahesh YADAV, Suchit JHUNJHUNWALA, Jennie LILL
  • Publication number: 20240409657
    Abstract: The present disclosure provides methods for treating lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. In other aspects, the present disclosure provides methods for treating membranous nephropathy.
    Type: Application
    Filed: August 23, 2024
    Publication date: December 12, 2024
    Applicant: Genentech, Inc.
    Inventor: Matthew Dominic CASCINO
  • Publication number: 20240409599
    Abstract: The invention provides stabilized IL-18 polypeptides and methods of making and using the same.
    Type: Application
    Filed: May 21, 2024
    Publication date: December 12, 2024
    Applicant: Genentech, Inc.
    Inventors: Travis William Bainbridge, Beyza Bulutoglu Baykara, Jonathan Thomas Sockolosky
  • Publication number: 20240410009
    Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
    Type: Application
    Filed: August 26, 2024
    Publication date: December 12, 2024
    Applicant: GENENTECH, INC.
    Inventors: Michael Townsend, Alvernia Francesca Setiadi, Tracy Staton
  • Publication number: 20240409535
    Abstract: Provided herein are solid forms, salts, and formulations of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, processes and synthesis thereof, and methods of their use in the treatment of cancer.
    Type: Application
    Filed: May 2, 2024
    Publication date: December 12, 2024
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Cheol Keun CHUNG, Jie XU, Hans IDING, Kyle CLAGG, Michael DALZIEL, Alec FETTES, Francis GOSSELIN, Ngiap-Kie LIM, Andrew MCCLORY, Haiming ZHANG, Paroma CHAKRAVARTY, Karthik NAGAPUDI, Sarah ROBINSON
  • Publication number: 20240409615
    Abstract: The presently disclosed subject matter relates to multi-vector recombinase mediated cassette exchange approaches to achieve targeted integration of sequences of interest for the generation host cells expressing recombinant proteins, e.g., monoclonal antibodies, as well as compositions derived from the same, e.g., bispecific antibodies, and other complex format proteins, e.g., membrane protein complexes, and other difficult to express molecules.
    Type: Application
    Filed: June 24, 2024
    Publication date: December 12, 2024
    Applicant: Genentech, Inc.
    Inventors: Chi Kin Domingos Ng, Amy Shen, Gavin Christian Barnard
  • Publication number: 20240400976
    Abstract: Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides. produced by the methods herein are also provided.
    Type: Application
    Filed: April 30, 2024
    Publication date: December 5, 2024
    Applicant: Genentech, Inc.
    Inventors: Natarajan VIJAYASANKARAN, Steven J. MEIER, Sharat VARMA, Yi YANG